257 related articles for article (PubMed ID: 20375907)
1. Influence of blood pressure reduction on composite cardiovascular endpoints in clinical trials.
Verdecchia P; Gentile G; Angeli F; Mazzotta G; Mancia G; Reboldi G
J Hypertens; 2010 Jul; 28(7):1356-65. PubMed ID: 20375907
[TBL] [Abstract][Full Text] [Related]
2. Documentation of endpoint prevention with combination therapy in hypertension is urgently needed.
Kjeldsen SE; Oparil S; Hedner T; Narkiewicz K
Blood Press; 2007; 16(1):4-5. PubMed ID: 17453745
[No Abstract] [Full Text] [Related]
3. Antihypertensive therapy and de-stiffening of the arteries.
Safar ME; Jankowski P
Expert Opin Pharmacother; 2010 Nov; 11(16):2625-34. PubMed ID: 20977399
[TBL] [Abstract][Full Text] [Related]
4. Management of older hypertensive patients.
Hedner T; Kjeldsen S; Oparil S; Narkiewics K
Blood Press; 2008; 17(4):184-5. PubMed ID: 18932064
[No Abstract] [Full Text] [Related]
5. The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials.
Czernichow S; Zanchetti A; Turnbull F; Barzi F; Ninomiya T; Kengne AP; Lambers Heerspink HJ; Perkovic V; Huxley R; Arima H; Patel A; Chalmers J; Woodward M; MacMahon S; Neal B;
J Hypertens; 2011 Jan; 29(1):4-16. PubMed ID: 20881867
[TBL] [Abstract][Full Text] [Related]
6. [Arterial hypertension: an update].
Verdecchia P; Angeli F; Mazzotta G; Gentile G; Reboldi G
G Ital Cardiol (Rome); 2010 May; 11(5 Suppl 3):74S-77S. PubMed ID: 20879486
[No Abstract] [Full Text] [Related]
7. Are guidelines effectively guiding antihypertensive therapy?
Vasan RS; Kannel WB
Am J Cardiol; 2007 Jul; 100(1):143-4. PubMed ID: 17599457
[No Abstract] [Full Text] [Related]
8. Blood pressure lowering or selection of antihypertensive agent: which is more important?
Ruilope LM; Segura J
Nephrol Dial Transplant; 2006 Apr; 21(4):843-5. PubMed ID: 16384819
[No Abstract] [Full Text] [Related]
9. The blood pressure measurement--revisited.
Safar ME; Smulyan H
Am Heart J; 2006 Sep; 152(3):417-9. PubMed ID: 16923406
[No Abstract] [Full Text] [Related]
10. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
[TBL] [Abstract][Full Text] [Related]
11. Overcoming clinical inertia to achieve blood pressure goals: the role of fixed-dose combination therapy.
Basile J; Neutel J
Ther Adv Cardiovasc Dis; 2010 Apr; 4(2):119-27. PubMed ID: 20042448
[TBL] [Abstract][Full Text] [Related]
12. [Benefits of antihypertensive treatment. How much damage does it really prevent?].
Holzgreve H
MMW Fortschr Med; 2006 Apr; 148(14):47, 49-50. PubMed ID: 16669282
[No Abstract] [Full Text] [Related]
13. Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the future?
Dahlöf B; Devereux RB; Kjeldsen SE; Lyle PA; Zhang Z; Edelman JM
Blood Press; 2007; 16(1):6-12. PubMed ID: 17453746
[TBL] [Abstract][Full Text] [Related]
14. Ambulatory blood pressure monitoring in the prediction of cardiovascular events and effects of chronotherapy: rationale and design of the MAPEC study.
Hermida RC
Chronobiol Int; 2007; 24(4):749-75. PubMed ID: 17701685
[TBL] [Abstract][Full Text] [Related]
15. Antihypertensive treatment in the very elderly shows significant mortality benefit.
Cardiovasc J Afr; 2008; 19(3):169-71. PubMed ID: 18568185
[No Abstract] [Full Text] [Related]
16. Geriatric hypertension: aggressive therapy and its physiologic rationale.
Lakatta EG
Geriatrics; 1986 May; 41(5):44-53. PubMed ID: 3514379
[TBL] [Abstract][Full Text] [Related]
17. Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE study.
Nordestgaard BG; Kontula K; Benn M; Dahlöf B; de Faire U; Edelman JM; Eliasson E; Fyhrquist F; Hille DA; Ibsen H; Lyle PA; Berg K; Sandberg M; Sethi AA; Wong PH; Os I
Pharmacogenet Genomics; 2010 Feb; 20(2):77-85. PubMed ID: 20065889
[TBL] [Abstract][Full Text] [Related]
18. Redefining efficacy of antihypertensive therapies beyond blood pressure reduction--the role of angiotensin II antagonists.
Conlin PR
Int J Clin Pract; 2005 Feb; 59(2):214-24. PubMed ID: 15854200
[TBL] [Abstract][Full Text] [Related]
19. Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint reduction in hypertension study.
Kjeldsen SE; Devereux RB; Hille DA; Lyle PA; Dahlöf B; Julius S; Edelman JM; Snapinn SM; de Faire U; Fyhrquist F; Ibsen H; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
Blood Press; 2009; 18(6):348-61. PubMed ID: 20001655
[TBL] [Abstract][Full Text] [Related]
20. You should treat patients over the age of 80 who have hypertension.
Lundberg GD
Medscape J Med; 2008; 10(8):185. PubMed ID: 18924637
[No Abstract] [Full Text] [Related]
[Next] [New Search]
